AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to risankizumab (ABBV-066) for the investigational treatment of Crohn’s disease in pediatric patients

Pediatric patients afflicted with Crohn’s disease may experience a delay in growth and sexual maturation and have symptoms similar to those seen in adults, including diarrhea, abdominal pain, rectal bleeding, and weight loss. 

Related Articles

Risankizumab, an IL-23 inhibitor, is being studied for immunological disorders such as Crohn’s disease, psoriasis, psoriatic arthritis, and asthma. It is being developed in collaboration with Boehringer Ingelheim.

For more information call (800) 633-9110 or visit AbbVie.com